Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.45)
# 250
Out of 5,182 analysts
132
Total ratings
50%
Success rate
22.96%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Buy | $56 → $48 | $9.29 | +416.68% | 8 | Apr 21, 2026 | |
| FBLG FibroBiologics | Maintains: Buy | $4 → $8 | $1.36 | +488.24% | 10 | Apr 16, 2026 | |
| KOD Kodiak Sciences | Reiterates: Buy | $38 → $58 | $45.43 | +27.67% | 10 | Mar 27, 2026 | |
| SRZN Surrozen | Reiterates: Buy | $32 → $36 | $30.98 | +16.20% | 4 | Mar 24, 2026 | |
| FDMT 4D Molecular Therapeutics | Reiterates: Buy | $36 | $9.46 | +280.55% | 19 | Mar 20, 2026 | |
| ALDX Aldeyra Therapeutics | Downgrades: Neutral | $10 → $2 | $1.57 | +27.39% | 14 | Mar 18, 2026 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $44 | $18.01 | +144.31% | 7 | Mar 17, 2026 | |
| IMUX Immunic | Maintains: Buy | $80 → $50 | $10.75 | +365.12% | 8 | Mar 2, 2026 | |
| ARDX Ardelyx | Maintains: Buy | $10 → $18 | $5.97 | +201.51% | 2 | Feb 20, 2026 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $6 | $1.42 | +322.54% | 4 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $25.89 | +116.30% | 13 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $11.33 | +129.48% | 11 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $88 | $62.09 | +41.73% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $6.22 | +92.93% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $5.00 | +60.00% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 | $9.60 | -6.25% | 8 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $637.74 | -95.61% | 1 | Aug 22, 2023 |
LENZ Therapeutics
Apr 21, 2026
Maintains: Buy
Price Target: $56 → $48
Current: $9.29
Upside: +416.68%
FibroBiologics
Apr 16, 2026
Maintains: Buy
Price Target: $4 → $8
Current: $1.36
Upside: +488.24%
Kodiak Sciences
Mar 27, 2026
Reiterates: Buy
Price Target: $38 → $58
Current: $45.43
Upside: +27.67%
Surrozen
Mar 24, 2026
Reiterates: Buy
Price Target: $32 → $36
Current: $30.98
Upside: +16.20%
4D Molecular Therapeutics
Mar 20, 2026
Reiterates: Buy
Price Target: $36
Current: $9.46
Upside: +280.55%
Aldeyra Therapeutics
Mar 18, 2026
Downgrades: Neutral
Price Target: $10 → $2
Current: $1.57
Upside: +27.39%
Zenas BioPharma
Mar 17, 2026
Reiterates: Buy
Price Target: $44
Current: $18.01
Upside: +144.31%
Immunic
Mar 2, 2026
Maintains: Buy
Price Target: $80 → $50
Current: $10.75
Upside: +365.12%
Ardelyx
Feb 20, 2026
Maintains: Buy
Price Target: $10 → $18
Current: $5.97
Upside: +201.51%
Akebia Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $6
Current: $1.42
Upside: +322.54%
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $25.89
Upside: +116.30%
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $11.33
Upside: +129.48%
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $62.09
Upside: +41.73%
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $6.22
Upside: +92.93%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $5.00
Upside: +60.00%
May 19, 2025
Reiterates: Neutral
Price Target: $9
Current: $9.60
Upside: -6.25%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $637.74
Upside: -95.61%